From the Boardroom: Venture Debt Financing a Life Sciences Company
Veteran life sciences professionals provided an insider’s perspective on key considerations in venture debt financing for a life sciences company. Our panel of insiders weighed in on important questions, including:
-
When is it the right time?
-
What are the dilution considerations vs. equity financing?
-
What are the complexities associated with syndicated deals?
-
Should venture debt be part of an overall financing strategy?
A wine reception followed, sponsored by Silicon Valley Bank.
Confirmed Speakers included:
- David Clapper - CEO, Minerva Surgical, Inc.
- Ron Eastman - Managing Director, Essex Woodlands Health Ventures
- Caroline Loewy - CFO, Tobira Therapeutics
- Amy Olson - Senior Finance Attorney, Ropes & Gray LLP
- Pete Scott - Head of Life Sciences, Silicon Valley Bank